JP6553067B2 - 糖尿病および肝疾患を治療するための組成物および方法 - Google Patents

糖尿病および肝疾患を治療するための組成物および方法 Download PDF

Info

Publication number
JP6553067B2
JP6553067B2 JP2016550869A JP2016550869A JP6553067B2 JP 6553067 B2 JP6553067 B2 JP 6553067B2 JP 2016550869 A JP2016550869 A JP 2016550869A JP 2016550869 A JP2016550869 A JP 2016550869A JP 6553067 B2 JP6553067 B2 JP 6553067B2
Authority
JP
Japan
Prior art keywords
liver
group
composition
unit dosage
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016550869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505785A (ja
JP2017505785A5 (OSRAM
Inventor
フェルナンデス，プラブハバシ
Original Assignee
センプラ ファーマシューティカルズ，インコーポレイテッド
センプラ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センプラ ファーマシューティカルズ，インコーポレイテッド, センプラ ファーマシューティカルズ，インコーポレイテッド filed Critical センプラ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2017505785A publication Critical patent/JP2017505785A/ja
Publication of JP2017505785A5 publication Critical patent/JP2017505785A5/ja
Application granted granted Critical
Publication of JP6553067B2 publication Critical patent/JP6553067B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2016550869A 2014-02-14 2015-02-11 糖尿病および肝疾患を治療するための組成物および方法 Active JP6553067B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461939961P 2014-02-14 2014-02-14
US61/939,961 2014-02-14
US201461984225P 2014-04-25 2014-04-25
US61/984,225 2014-04-25
US201462086911P 2014-12-03 2014-12-03
US62/086,911 2014-12-03
PCT/US2015/015353 WO2015123256A1 (en) 2014-02-14 2015-02-11 Compositions and methods for treating diabetes and liver diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019124815A Division JP2019189639A (ja) 2014-02-14 2019-07-03 糖尿病および肝疾患を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017505785A JP2017505785A (ja) 2017-02-23
JP2017505785A5 JP2017505785A5 (OSRAM) 2018-03-22
JP6553067B2 true JP6553067B2 (ja) 2019-07-31

Family

ID=53800574

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016550869A Active JP6553067B2 (ja) 2014-02-14 2015-02-11 糖尿病および肝疾患を治療するための組成物および方法
JP2019124815A Pending JP2019189639A (ja) 2014-02-14 2019-07-03 糖尿病および肝疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019124815A Pending JP2019189639A (ja) 2014-02-14 2019-07-03 糖尿病および肝疾患を治療するための組成物および方法

Country Status (12)

Country Link
US (1) US20170165286A1 (OSRAM)
EP (1) EP3105234A4 (OSRAM)
JP (2) JP6553067B2 (OSRAM)
KR (1) KR20160113307A (OSRAM)
CN (1) CN106132969A (OSRAM)
AU (1) AU2015217293A1 (OSRAM)
CA (1) CA2939076A1 (OSRAM)
IL (1) IL247152A0 (OSRAM)
MX (1) MX2016010447A (OSRAM)
RU (1) RU2016133471A (OSRAM)
WO (1) WO2015123256A1 (OSRAM)
ZA (1) ZA201606199B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9072759B2 (en) 2008-10-24 2015-07-07 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
IN2014DN08939A (OSRAM) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CA3111317C (en) 2012-09-17 2023-08-29 F. Hoffmann-La Roche Ltd. Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN105163785A (zh) 2013-03-14 2015-12-16 森普拉制药公司 用于治疗呼吸道疾病的方法及其制剂
AU2017346871B2 (en) * 2016-10-18 2023-08-03 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist
WO2018094265A2 (en) * 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
CA2411293A1 (en) * 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2897154B1 (fr) * 2006-02-08 2008-03-07 Airbus France Sas Dispositif pour construire et securiser une trajectoire de vol a basse altitude destinee a etre suivie par un aeronef.
EP2077271A4 (en) * 2006-05-01 2010-09-15 Taisho Pharmaceutical Co Ltd Macrolide derivative
JP5025249B2 (ja) * 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 発進クラッチ
JP5150740B2 (ja) * 2011-01-21 2013-02-27 株式会社小松製作所 作業車両
KR101618424B1 (ko) * 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
US9078975B2 (en) * 2011-09-30 2015-07-14 Becton Dickinson France, S.A.S. Syringe having pivoting arm plunger rod

Also Published As

Publication number Publication date
RU2016133471A (ru) 2018-03-19
WO2015123256A1 (en) 2015-08-20
JP2019189639A (ja) 2019-10-31
US20170165286A1 (en) 2017-06-15
AU2015217293A1 (en) 2016-09-01
EP3105234A1 (en) 2016-12-21
ZA201606199B (en) 2020-01-29
IL247152A0 (en) 2016-09-29
MX2016010447A (es) 2016-12-20
RU2016133471A3 (OSRAM) 2018-09-24
EP3105234A4 (en) 2017-11-08
CN106132969A (zh) 2016-11-16
CA2939076A1 (en) 2015-08-20
JP2017505785A (ja) 2017-02-23
KR20160113307A (ko) 2016-09-28

Similar Documents

Publication Publication Date Title
JP6553067B2 (ja) 糖尿病および肝疾患を治療するための組成物および方法
JP6879980B2 (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
US11419878B2 (en) Medicine obtained by combining FXR agonist and ARB
JP6238969B2 (ja) 新規方法
KR20170095894A (ko) 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6878596B2 (ja) Ｆｘｒアゴニストの組合せ
KR20080035997A (ko) 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
MX2013008410A (es) Procedimientos y coposiciones para tratar trastornos renales.
KR20190044667A (ko) Fxr 작용제의 신규 요법
TWI544921B (zh) 蛇床子素用於製備治療局部腎絲球硬化症之組合物的用途
KR20220038339A (ko) Sglt 억제제, 예를 들어 sglt 1/2 억제제를 포함하는 치료
KR20130113921A (ko) 비알코올성 지방성 간염의 예방 및/또는 치료제
CN117980001A (zh) 用于预防或治疗炎症性肠病的包含肠类器官和抗炎剂的药物组合物
HK1231075A1 (en) Compositions and methods for treating diabetes and liver diseases
US20070072937A1 (en) Pharmaceutical composition comprising alpha-lipoic acid for inflammatory diseases
JP6043997B2 (ja) 炎症性サイトカインの機能を抑制する炎症性疾患治療剤
JP2022514672A (ja) ヒアルロナン合成阻害のための４－メチルウンベリフェリルグルクロニド
US9937194B1 (en) Compounds and methods for treating inflammatory diseases
JP2022527762A (ja) オベチコール酸を用いた肝疾患の診断および処置の方法
CN107427480A (zh) 用于预防和/或治疗脂肪性肝炎的脂肪酸酰胺
CN118453879A (zh) 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用
HK1260722A1 (en) Medicine obtained by combining fxr agonist and arb
WO2012011572A1 (ja) 拡張不全型心不全治療薬
UA114190C2 (uk) Способи лікування фіброзу
HK1187539A (en) Methods and compositions for treating kidney disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190703

R150 Certificate of patent or registration of utility model

Ref document number: 6553067

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250